Research paper describes increase in potency of a GM-CSF-secreting tumor cell immunotherapy by a LAG-3 fusion protein immunopotentiator ORSAY, France, June 25th, 2008 - Immutep S.A., a biopharmaceutical company specialized in immunostimulatory and immunomodulatory treatments of cancer and infectious or autoimmune disease, announced today the publication of research conducted by Cell Genesys, Inc. showing that a lymphocyte activation gene-3 fusion protein increases the potency of a granulocyte macrophage colony-stimulating factor (GM-CSF)-secreting tumor cell immunotherapy. These data were published in the June issue of Clinical Cancer Research. The research team found that combining mLAG-3Ig with a murine GM-CSF-secreting tumor cell immunotherapy prolonged the survival of tumor-bearing animals compared to animals treated with...
[read full story]
Your Web Site
